valu usd unless otherwis note
surpris quarter reiter outperform
view collect evid tavr survey two recent
doctor day chicago nyc dinner event lead tavr expert
point scenario limit upsid ran contrari
prevail investor sentiment reflect ytd return vs
 base activ after-market risk/reward
assess favor buy weak
consolid result vs estim ww revenu
y/i cc line estim within guidanc
ww sale three product categori thv
sale cardioband mitral repair valv non-gaap ep
estim lower oper expens
lower tax rate contribut almost equal ep upsid
 thv sale grew mid-teen ew ceas provid actual
thv sale figur estim reflect growth
lower-volum center experienc faster tavr procedur
growth manag believ ew sale growth line
procedur growth worth note howev
report market growth rate higher ew state
gain share sinc launch evolut
tavr sale growth europ lag procedur growth low-double-
digit procedur growth occur intern gain share
europ analysi tavr sale data portico
acur neo respect suggest compani may
take share well although individu compani rel
small tavr rel ew ew commenc european
launch centera self-expand valv manag report
excel clinician feedback come surpris given
strength clinic data present
sapien ultra timelin re-affirmed ew ask european
regul run small trial augment exist clinic data
push potenti ce mark manag remain confid
ultra launch even though applic seek
approv reli least partial european data manag
share detail regulatori strategi ultra approv could
next major catalyst reacceler ew tavr sale growth
judg mdt success transit evolut evolut
chang revenu guidanc ep guidanc rais
manag repeat commentari earn tavr
consolid revenu toward high end guidanc
goe surgic valv critic ep
guidanc increas primarili
function lower tax rate revenu estim stay
ep estim increas
price prior trade day market close estimate unless otherwis note
capit market appreci consider institut investor all-america research survey
ew best growth stori large-cap
med-tech view believ ew post
revenu compound-annual-growth-rate double-digit ep compound-annual-growth-rate faster
large-cap compani coverag univers
manag project ww tavr market
low-double-digit compound-annual-growth-rate believ
conserv expect market cross threshold
year earlier exceed forecast includ
revenu contribut low risk indic start
manag forecast ww tavr market
conserv estim low-double-digit sale
compound-annual-growth-rate suffici
cross threshold end time period
among growth driver expect
bigger impact first half next decad
fda approv late patient
moder aortic stenosi asymptomat
next-gener valv expans emerg
forecast mitral tricuspid market
signific share ew manag forecast market
opportun transcathet therapi treat mitral
tricuspid regurgit
base forecast analysi suggest
ew mitral/tricuspid portfolio could sale
contribut come primarili devic
cardioband pascal ew expect ce mark
cardioband tr ce mark pascal mr
bloomberg capit market estim upside/downside/target
dcf model yield base case price target
key assumpt follow revenu growth
compound-annual-growth-rate driven double-digit growth
tavr/mitr franchis mid-single-digit growth
two product categori surgic valv critic
ebit margin
tax rate forecast period cash
flow dcf model discount use wacc
upsid scenario valu assum low-double-digit
revenu growth compound-annual-growth-rate driven
expans moder aortic stenosi asymptomat
along meaning revenu contribut
downsid scenario valu assum moder
tavr revenu growth due slower adopt among
intermedi risk patient delay approv low risk
indic stronger competit lack
progress mitral clinic develop program
exhibit ew result vs estim consensu
dcf model yield base case price target key assumpt follow
revenu growth compound-annual-growth-rate driven double-digit growth tavr/
mitral franchis mid-single-digit growth two product categori surgic
valv critic ebit margin tax rate
forecast period cash flow dcf model discount use
wacc price target basi outperform rate ew share
risk rate price target
risk price target rate includ limit increas competit
market opportun currenc litig reimburs clinic trial risk
edward lifesci global player product technolog design treat
cardiovascular diseas compani focus specif cardiovascular opportun
includ heart valv diseas critic care technolog peripher vascular diseas
